Transcatheter occlusion of the left atrial appendage for stroke prevention

Expert Review of Cardiovascular Therapy

Volumn 3, Issue 6, 2005, Pages 1003-1008

  Bayard, Yves L ^a   Ostermayer, Stefan H ^a   Sievert, Horst ^a  

^a CARDIOVASCULAR CENTER FRANKFURT   (Germany)

Author keywords

Amplatzer; Anticoagulation; Atrial fibrillation; Left atrial appendage; PLAATO ; Stroke; WATCHMAN

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FEASIBILITY STUDY; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HIGH RISK PATIENT; HUMAN; IMPLANTATION; LIVER TOXICITY; LONG TERM CARE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SAFETY; THROMBOEMBOLISM; THROMBOGENESIS; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

ATRIAL APPENDAGE; CEREBROVASCULAR ACCIDENT; HEART ATRIA; HEART CATHETERIZATION; HUMANS; PROSTHESES AND IMPLANTS;

EID: 28644446215     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.3.6.1003     Document Type: Review

References (27)

1. Veinot JP, Harrity PJ, Gentile F et al. Anatomy of the normal left atrial appendage. Circulation 96, 3112-3115 (1997).
2. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann. Thorac. Surg. 61, 755-759 (1996).
3. Fuster V, Rydén LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). J. Am. Coll. Cardiol. 38, 1231-1265 (2001).
4. Go AS, Hylek EM, Borowsky LH et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (Atria) study. Ann. Intern. Med. 131, 927-934 (1999).
5. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann. Intern. Med. 128(8), 639-647 (1998).
6. Meier B, Palacios I, Windecker S et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patents with atrial fibrillation. Catheter Cardiovasc. Interv. 60, 417-422 (2003).
7. Sievert H, Lesh MD, Trepels T et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation-early clinical experience. Circulation 105, 1887-1889 (2002).
8. Ostermayer SH, Reisman M, Kramer PH et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO™ System) to prevent stroke in high-risk patients with nonrheumatic atrial fibrillation -results from the international multicenter feasibility trials. J. Am. Coll. Cardiol. 46(1), 9-14 (2005).
9. Fischer E, Heyder O, Thuesen L et al. Left atrial appendage occlusion to prevent stroke in suboptimal warfarin candidates: current results of the European Multicenter Registry trial. J. Am. Coll. Cardiol. 45(3 Suppl. A), A14 (2005) (Abstract).
10. Bayard Y, Omran H, Kramer P et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO) worldwide experience. 8th International Workshop Catheter Interventions in Congenital and Structural Heart Disease, Frankfurt, Germany, 54-55 (2005) (Abstract).
11. Gage BF, van Walraven C, Pearce L et al. Selecting patients with atrial fibrillation for anticoagulation - stroke risk stratification in patients taking aspirin. Circulation. 110, 2287-2292 (2004).
12. Sick P, Muth G, Ulrich M et al. Early clinical experience with the WATCHMAN®-closure device for left atrial appendage to prevent thromboembolic complications in patients with non-valvular atrial fibrillation. Presented at the Transcatheter Cardiovascular Therapeutics symposium, Washington DC, USA, September 27-October 1(2004).
13. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285(22), 2864-2870 (2001).
14. Meier B. Left atrial appendage closure -amplatzer devices. 7th International Workshop Catheter Interventions in Congenital Heart Disease and Other Non-Coronary Interventions, Frankfurt am Main, Germany, 187 (2004) (Abstract).
15. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35(1), 183-187 (2000).
16. Sandercock P, Bamford J, Dennis M et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long-term prognosis (Oxfordshire Community Stroke Project). BMJ 305, 1460-1465 (1992).
17. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am. Heart J. 131, 790-795 (1996).
18. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am. J. Cardiol. 82, N2-N9 (1998).
19. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983-988 (1991).
20. Hart RG, Halperin JL, Pearce LA et al. Lessons from the stroke prevention in atrial fibrillation trials. Ann. Intern. Med. 138, 831-838 (2003).
21. Levine MN, Raskob G, Landefeld S et al. Hemorrhagic complications of anticoagulant treatment. Chest 119, S108-S121 (2001).
22. Stafford R, Singer D. Recent national patterns of warfarin use in atrial fibrillation. Circulation 97, 1231-1233 (1998).
23. Executive Steering Committee, on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362, 1691-1698 (2003).
24. SPORTIF Executive Steering Committee for the SPORTIF V Investigators. Ximelagatran vs. Warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293(6), 690-698 (2005).
25. Madden J. Resection of the left auricular appendix. JAMA 140, 769-772 (1948).
26. Bonow RO, Carabello B, de Leon AC et al. ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on management of patients with valvular heart disease). J. Am. Coll. Cardiol. 32, 1486-1582 (1998).
27. Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I. Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. 36(2), 468-471 (2000).